Pancreatic Cancer Research

ResearcherTel Aviv UniversityActive in the last 2 years

Ido Nachmany

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-2612-8555; OpenAlex author ID A5013862238. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 3 papers · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 11

  1. Transcriptomics of Upper Gastrointestinal Fluids Can Diagnose Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jcmgh.2026.101776↗
  2. Elevated Carcinoembryonic Antigen Levels Predict Failure to Reach Surgery in Patients with Borderline Resectable Pancreatic Cancer Referred to Neoadjuvant Ther… Co-author DOI 10.1245/s10434-025-17433-3↗
  3. Pancreatic Cancer with Liver Oligometastases-Different Patterns of Disease Progression May Suggest Benefits of Surgical Resection. Co-author DOI 10.3390/jcm14155538↗
  4. Should we resect distant metastases?-reconsidering radical resection of pancreatic cancer with liver metastases. First author DOI 10.21037/hbsn-24-322↗
  5. Perioperative Platelet Count Ratio Predicts Long-Term Survival after Left Pancreatectomy and Splenectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.3390/jcm13041050↗
  6. Prognostic significance of pancreatic fistula and postoperative complications after pancreaticoduodenectomy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surge.2019.07.003↗
  7. Palliative bypass surgery for patients with advanced pancreatic adenocarcinoma: experience from a tertiary center. Co-author DOI 10.1186/s12957-020-01828-5↗
  8. Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08469-8↗
  9. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Co-author DOI 10.1016/j.ejso.2018.07.057↗
  10. Number of evaluated lymph nodes and positive lymph nodes, lymph node ratio, and log odds evaluation in early-stage pancreatic ductal adenocarcinoma: numerology… Co-author DOI 10.1186/s12957-016-0983-5↗
  11. Pancreatic cancer: surgery is a feasible therapeutic option for elderly patients. Co-author DOI 10.1186/1477-7819-9-10↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Niv Pencovich · 6 shared papers, 2020–2026 · strength 1.51
  2. Ron Pery · 4 shared papers, 2024–2026 · strength 0.94
  3. Talia Golan · 3 shared papers, 2020–2025 · strength 0.56
  4. Nedaa Mahamid · 2 shared papers, 2025 · strength 0.46
  5. Arielle Jacover · 2 shared papers, 2025 · strength 0.46
  6. Guy Lahat · 5 shared papers, 2011–2020 · strength 0.36
  7. Nir Lubezky · 5 shared papers, 2011–2020 · strength 0.36
  8. Joseph M. Klausner · 4 shared papers, 2016–2020 · strength 0.34
  9. Tal Barkai · 1 shared paper, 2026 · strength 0.28
  10. Ido Wolf · 3 shared papers, 2016–2020 · strength 0.23
  11. Hallbera Gudmundsdottir · 1 shared paper, 2024 · strength 0.20
  12. Alex Barenboim · 2 shared papers, 2018–2020 · strength 0.17
  13. Uri Neeman · 1 shared paper, 2020 · strength 0.11
  14. Boaz Sagie · 1 shared paper, 2020 · strength 0.11
  15. Lior Orbach · 1 shared paper, 2020 · strength 0.11
  16. Eran Nizri‏ · 1 shared paper, 2016 · strength 0.05
  17. Josef M. Klausner · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.